The invention relates to a pharmaceutical composition comprising liposomes composed of non-charged vesicle-forming lipids, optionally including not more than 10 mole percent of negatively charged vesicle-forming lipids and/or not more than 10 mole percent of PEGylated lipids, the liposomes having a selected mean particle diameter in the size range of 40-200 nm and comprising a first corticosteroid in water soluble form, for the site-specific treatment of inflammatory disorders in humans, providing in human patients a fast, strong, and durable anti-inflammatory effect for at least 2 weeks at a dose of at most 5 mg/kg body weight of prednisolone or an equipotent dose corticosteroid other than prednisolone at a treatment frequency of at most once per two weeks. Furthermore the present invention relates to the application of the above-mentioned pharmaceutical composition given as intervention therapy in inflammatory disorders such as rheumatic disease or a related inflammatory connective tissue disorder, inflammatory diseases of the kidney or inflammatory bowel disorders, in combination with chronic therapy with a second free corticosteroid formulation or in combination with chronic treatment with a disease-modifying agent such as methotrexate.Cette invention concerne une composition pharmaceutique comprenant des liposomes composés de lipides formant des vésicules non chargés qui, éventuellement ne contiennent pas plus de 10 % en mole de lipides formant des vésicules chargés négativement et/ou pas plus de 10 % en mole de lipides pégylés, les liposomes ayant un diamètre particulaire moyen compris entre 40 et 200 nm et comprenant un premier corticostéroïde soluble dans l'eau, pour le traitement spécifique des affections inflammatoires chez l'homme, produisant chez l'homme un effet anti-inflammatoire rapide, fort et durable pendant au moins 2 semaines à une dose d'au plus 5 mg/kg de poids corporel de prednisolone ou une dose équipotente de corticostéroïde autre que la pred
